ArticleAnnals of medicine2025
Bleeding risk and prediction model to predict bleeding risk of tissue biopsy for definitive diagnosis in patients with suspected amyloidosis.
Article in Annals of medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Renal amyloidosis prediction in kidney disease patients accompanied by monoclonal gammopathy.British journal of haematology · 2026Article
- Comparative Histopathological Characteristics of Duodenal Involvement in Different Types of Amyloidosis.Biomedicines · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionBleeding from the affected organs is a common manifestation of amyloidosis. The risk for perioperative bleeding in patients with amyloidosis remains controversial. In this study, we aimed to compare the bleeding risk of tissue biopsies for a definitive diagnosis between patients with and without amyloidosis, identify risk factors, and generate a prediction model for bleeding risk in these patients.
methodsWe enrolled patients aged >15 years who had amyloidosis as part of their differential diagnosis before tissue biopsy. After obtaining histopathological reports, we randomly selected patients with and without amyloidosis at a ratio of 4:1.
resultsA total of 360 patients were enrolled before tissue biopsy. Bleeding complications were observed in 5.6% and 4.2% of patients with and without amyloidosis, respectively. Amyloidosis was not associated with an increased perioperative bleeding risk (adjusted odds ratio 1.19; 95% confidence interval 0.17-8.41,
conclusionsAmyloidosis is not associated with an increased risk of bleeding in tissue biopsies. The KiHPL model can predict the bleeding risk of tissue biopsies for a definitive diagnosis in patients with suspected amyloidosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.